The Great Debate: Why WHO Withheld Weight-Loss GLP-1 Drugs from its Essential Medicines List

Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection

A Glimmer of Hope: Weight-Loss Drugs Show Remarkable Potential for Painful Skin Condition

Unlocking Tomorrow's Cures: Three Biotech Catalysts Igniting a New Era of Investment

Serena Williams Opens Up: Why She Chose the Natural Path Over GLP-1 Treatments Post-Pregnancy

A Breakthrough in Affordability: Ozempic Now Half Price for Cash Customers Through GoodRx Partnership

Healthcare Titans: UnitedHealth vs. Novo Nordisk – Which Giant Dominates Your Portfolio?

Viking Therapeutics' Oral Weight Loss Drug Stumbles: VK2735 Data Leaves Investors Underwhelmed

The Wild West of Weight Loss: Unpacking the Perils of Online Compounded GLP-1s